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a1-Antitrypsin (AAT) is the archetype member of the serine protease inhibitor (SERPIN ) super-
gene family. The AAT deficiency is most often associated with the Z mutation, which results in
abnormal Z AAT folding in the endoplasmic reticulum of hepatocytes during biogenesis. This
causes intra-cellular retention of the AAT protein rather than efficient secretion with conse-
quent deficiency of circulating AAT. The reduced serum levels of AAT contribute to the devel-
opment of chronic obstructive pulmonary disease (COPD) and the accumulation of abnormally
folded AAT protein increases risk for liver diseases. In this review we show that with the
discovery of AAT deficiency in the early 60s as a genetically determined predisposition to
the development of early-onset emphysema, intensive investigations of enzymatic mecha-
nisms that produce lung destruction in COPD were pursued. To date, the role of AAT in other
than lung and liver diseases has not been extensively examined. Current findings provide new
evidence that, in addition to protease inhibition, AAT expresses anti-inflammatory, immuno-
modulatory and antimicrobial properties, and highlight the importance of this protein in health
and diseases. In this review co-occurrence of several diseases with AAT deficiency is discussed.
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The protease inhibitor activity of human plasma was first
discovered by Fermi and Pernossi in 1894.1 However, the
isolation and characterization of individual proteins have only
emerged much later with the availability of new techniques.
Ultimately, the so-called serum trypsin inhibitor responsible
for antiprotease activity was first isolated in 1955 by Schultze
and nameda1-antitrypsin because of its occurrence in the a1-
globulin fraction and its ability to inhibit trypsin.2
a1-Antitrypsin (AAT), also referred to as alpha1-proteinase
inhibitor or SERPINA1, and is the prototypical member of the
SERPIN (an acronym for serine proteinase inhibitor) family of
protease inhibitors. The term SERPIN was introduced as by
Carrell and Travis in 1985 to describe a superfamily of serine
protease inhibitors of mammalian plasma.3 Serpin-like genes
have subsequently been identified in animals, poxviruses,
plants, bacteria and archaea, and over 1500 members of this
family have been described to date.4
AAT synthesis and regulation
AAT is mainly produced (70e80%) by liver cells, but it is also
synthesized by monocytes, macrophages, pulmonary alve-
olar cells, and by intestinal and corneal epithelium.5e8 De
novo synthesis of AAT has also been demonstrated in human
cancer cells.9
The normal plasma concentration of AAT ranging from 0.9
to 1.75 g/L and the protein is cleared with a half-life of 3e5
days.10 AAT is also present in saliva, tears,milk, semen, urine
and bile11e15 .The distribution of the protein is not uniform:
for example, in the epithelial lining fluid of the lower respi-
ratory tract its concentration is suggested to be about 10% of
plasma levels.16 As an acute-phase reactant, plasma AAT
levels increase rapidly (3e4 fold) in response to inflammation
or infection. The concentration of AAT in plasma also
increases during oral contraceptive therapy and pregnancy.
During an inflammatory response, tissue concentrations of
AAT may increase as much as 11-fold as a result of local
synthesis by resident or invading inflammatory cells.16,17 For
example, human alveolar macrophages can contribute totissue AAT levels in response to inflammatory cytokines (IL-6,
IL-1 and TNFa) and endotoxins.18,19 The expression of AAT by
alpha and delta cells of human islets20 and intestinal
epithelial cells21 is also enhanced by cytokines. AATsynthesis
by corneal epithelium, on the other hand, appears to be
under the influence of retinol, IL-2, fibroblast growth factor-
2, and insulin-like growth factor-1. Interestingly, AAT
expression also shows some degree of substrate and/or auto-
regulation with enhanced synthesis following exposure to
elastase alone or as a complex of AAT.22
Protease inhibitory activity of AAT
Until recently it was thought that inhibition of neutrophil
elastase and proteinase 3 (PR3) is the primary function of
AAT.23 Current studies demonstrate that AAT is an irreversible
inhibitor for kallikreins 7 and 1424, and that AAT also inhibits
intra-cellular and cell-surface proteases. Matriptase, a cell-
surface serineprotease involved in the activation of epithelial
sodium channels, is one such protease. Findings that AAT
inactivates the catalytic domain of matriptase in vitro and
inhibits epithelial sodium transport both in vitro and in
vivo25e27 support the notion that the inhibition of matriptase
by AAT may offer a pharmacologic target for improving
mucociliary clearance in both COPD and cystic fibrosis.
Several studies have shown that AAT inhibits the activity of
caspase-3, an intra-cellular cysteine protease which plays an
essential role in cell apoptosis.28,29 A recent study by Bergin
and collaborators, provides newevidence that AATmodulates
neutrophil chemotaxis in response to soluble immune
complexes by inhibiting ADAM-17 activity, also called TACE
(tumor necrosis factor-a-converting enzyme).30
Other biological activities of AAT
AAT has been reported to play an immunoregulatory
role,31,32 to inhibit neutrophil superoxide production,33 to
enhance insulin-induced mitogenesis in various cell lines,34
and to induce a IL-1 receptor antagonist expression.35 In
vivo, AAT has been shown to protect against TNFa or endo-
toxin-induced lethality.36,37 Findings that AAT enhances the
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a role of AAT in ironmetabolism.38 AAT has also been found to
bind to the secreted enteropathogenic Escherichia coli
proteins (EspB, EspD), thereby reducing their hemolysis of
red blood cells.39 An interaction between AAT and Crypto-
sporidium parvum,40 a protozoan parasite, has been shown
to inhibit Cryptosporidium parvum infection, suggesting
a potential role for AAT in cryptosporidiosis. Aerosolized AAT
also suppressed bacterial proliferation in a rat model of
chronic Pseudomonas aeruginosa lung infection and in
patients with cystic fibrosis.41 It has recently been demon-
strated that a specific 20-residue fragment of AAT
(C-terminal peptide, residues 377e396, referred to as VIRIP)
binds to the gp41 fusion peptide of HIV-1 and prevents the
virus from entering target cells, thereby inhibiting HIV-1
infection.42 These findings suggest that AAT may play
a protective role in HIV-1-infected individuals.43
In vitro, AAT was demonstrated to inhibit endotoxin-
stimulated TNFa and to enhance IL-10 expression in human
monocytes, mediated by signaling through the cAMP-
dependent protein kinase A pathway which is targeted by
a number of anti-inflammatory drugs used and/or currently
under development for COPD.44 AAT also expresses a broad
anti-inflammatory profile in gene expression studies on
primary human lung microvascular endothelial cells,
including the suppression of self-induced TNFa expression.45
Animal studies provide further evidence that AAT therapy
prolongs islet graft survival in transplanted allogeneic dia-
betic mice.46,47 Current findings show that AAT stimulates
insulin secretion and protects b-cells against cytokine-
induced apoptosis, and these effects of AAT also seem to be
mediated through the cAMP pathway. In view of these novel
findings, it is suggested that AAT may represent an anti-
inflammatory compound to protect b-cells under immuno-
logical attack in type 1 diabetes and also therapeutic
strategy to potentiate insulin secretion in type 2 diabetes.48
Interestingly, complexes between AAT and other proteins
have been associated with specific diseases. In sera from
patients with myeloma, Bence-Jones proteinemia complexes
between AAT and the kappa light chain of immunoglobulins
were detected.49 In plasma from diabetic subjects,
complexes of AATwith factor XIa andwith heat shock protein-
70 (HSP70), as well as glycosylated forms of AAT were
found.50,51 Moreover, complexes between immunoglobulin A
and AAT have been detected in the sera and synovial fluid of
patients with rheumatoid arthritis, systemic lupus eryth-
ematosus and ankylosing spondylitis.52 Human tissue kalli-
krein 3, known as a prostate-specific antigenwhich correlates
with prostate hypertrophy and malignancy, is also found to
bind to AAT in sera of subjects with high prostate-specific
antigen concentrations.53 Localization of AAT and AAT-low-
density-lipoprotein complexes in atherosclerotic lesions, and
enhanced degradation of AAT-low-density-lipoprotein by
macrophages suggested the involvement of the complex in
atherogenesis.54 So far, the factors driving assembly of AAT
with other proteins and the biological roles of such complexes
warrant further investigations.
Discovery of a1-antitrypsin deficiency (AATD)
In 1952, C-B Laurell at Malmo¨ University Hospital made
outstanding contributions to protein research by introducingplasma protein electrophoresis as a tool for clinical investi-
gations. By using electrophoresis, clinicians in respiratory
medicine in Malmo¨ unexpectedly noted the absence of the
alpha1 band in two patients, both of whom suffered from
severe respiratory insufficiency caused by emphysema. This
observation, published in 1963 by C-B Laurell and S Eriksson,
established that AAT deficiency (AATD) is inherited and linked
toemphysema. In the following years, several researchgroups
in Europe and the USA demonstrated that AAT is an effective
inhibitor of neutrophil elastase, thereby implicating elastase
in the pathogenesis of emphysema. Based on these develop-
ments, it was generally accepted that the protease-anti-
protease balance is an essential requirement for respiratory
health.55 Later, in a classical paper from 1978 by Larsson and
collaborators, it was convincingly demonstrated that the age
of onset of emphysema inAATDpersonswhowerealso current
or ex-smokers was very rapidly reduced.56
Since AAT is produced mainly in the liver, investigators in
Malmo¨ expected to find abnormal liver function in AATD
patients. Eriksson wrote that in 1962 they had seen a patient
with cryptogenic, decompensated cirrhosis who also lacked
the AAT band in the electrophoresis strip. Unfortunately, the
finding was misinterpreted in the belief that the patient had
developed an acquired AATD secondary to a severely
impaired liver function.56 The association between liver
diseases and inherited AATD was documented in the USA by
Sharp and colleagues in 1969.57 These observations were
explained in the 1990s when Lomas and his group in Cam-
bridge showed that the mutant AAT in deficient patients
forms intra-hepatic polymers due to the insertion of the
reactive center loop of onemolecule into the openedB-sheet
of the next.58
The detection of AAT variants became the greatest chal-
lenge from 1963 to 1978. The Pi-system was developed,
basedon themigration of theAATvariants in anelectric field.
The position of themigrated proteins is identified by a letter,
where M is normal, while the positions of the slower-moving
proteins are marked by letters before M in the alphabet and
these of the faster-moving proteins are denoted by letters
after M. Soon it became apparent that the underlying
abnormalities of the AAT variants were due to single amino
acid substitutions. By 1975, Carrell and co-workerswere able
to show that the S variant is due to the substitution of a glu-
tamic acid by a valine at position 264 inAAT.59 Soon after this,
the abnormality of Z AAT (glutamic acid substitution by
lysine) was explained by Jeppson in Malmo¨.60 Moreover, it
was shown that themutation in Z AAT does not affect protein
synthesis, but causes a perturbation of structure that results
in defective secretion of the protein.61,62 Thus, cases of
inherited AATD traceable to genetic mutations firmly
demonstrated the clinical importance of AAT in determining
susceptibility to chronic inflammatory conditions, including
COPD and liver diseases (Fig. 1).Prevalence of AATD
The highest prevalence of the Z deficiency variant of AAT is
recorded in Northwest European countries and North
America63 (Table 1). The Swedish neonatal screening per-
formed in 1972e74 greatly contributed to our knowledge of
AATD epidemiology,64 and permitted determination of a Z
Figure 1 a-1 Antitrypsin deficiency (AATD) is an inherited disorder affecting mainly the liver and lung. Today it is well established
that the Z, and also Siiyama (Ser53Phe) and Mmalton (52Phe del) variants of AAT form polymers and retain in the endoplasmic
reticulum of the hepatocytes. The retention of AAT within hepatocytes results in protein overload that in turn is associated with
juvenile hepatitis, cirrhosis, and hepatocellular carcinoma. Individuals with AATD have about 90% reduced levels of serum AAT and
are at greatly increased risk for early-onset COPD, especially if they are cigarette smokers.
Table 1 Estimated percentages of individuals with a-1
Antitrypsin genotypes SZ, ZZ, and SS among the total pop-
ulation of selected countries.
Country a1-Antitrypsin genotype
SZ ZZ SS
Austria 0.053 0.018 0.041
Belgium 0.181 0.028 0.295
Denmark 0.151 0.073 0.078
Estonia 0.061 0.061 0.016
Finland 0.010 0.004 0.005
France 0.195 0.017 0.578
Germany 0.041 0.010 0.044
Hungary 0.034 0.005 4.762
Italy 0.075 0.027 0.052
Latvia 0.282 0.204 0.098
Lithuania 0.051 0.023 0.028
The Netherlands 0.044 0.010 0.046
Poland 0.012 0.002 0.022
Portugal 0.356 0.019 1.667
Russia 0.007 0.001 0.009
Spain 0.360 0.030 1.087
Sweden 0.113 0.053 0.060
UK 0.065 0.014 0.075
US African American 0.006 0.002 0.022
US Caucasian 0.022 0.036 0.052
Table is based on the study publised by Blanco I et al., 2006.63
1132 S.M. Janciauskiene et al.gene frequency of 0.026. Another survey in Denmark yiel-
ded a Z frequency of 0.049.65 The prevalence of the Z AAT
genotype decreases throughout Europe along a north-
west—>south-east gradient.66 The distribution of the S
variant of AAT differs markedly from that of Z, the highest
frequency being reported in Southern Europe, and peaking
in the Iberian Peninsula (frequency > 0.1400).67 On the
other hand, these mutant gene frequencies are very low in
the Far East (0.00002 in Japan, 0 in China, and 0.0061
in South Korea).68 The frequencies of Z and S AAT variants
in North America, Australia and New Zealand are very
similar (0.012 and 0.035, respectively), which is further
support for the hypothesis that AATD arose in European
population. Some scientists estimate that the Z AAT
mutation arose between 7000 and 4000 years ago69 in
Southern Scandinavia, and subsequently was spread to
other European countries. In contrast, the high prevalence
of the S mutation in the Iberian peninsula indicates that this
variant most likely arose in the Portuguese population.70
Diagnosis of AATD
To date, approximately 100 different alleles of the AAT gene
(SERPINA1; MIM# 107400) have been identified and named
according to the Pi classification scheme.71 Moreover, avail-
able AAT variants have been categorized as normal (M),
deficient (most common Z and S), dysfunctional or null
variants.69,72 With regard to AATD, the “null”alleles are
associated with no detectable AAT in the serum, while the
“deficient” alleles lead to a decrease in plasma AAT. The AAT
genes are inherited as co-dominant alleles (products of both
Figure 2 Computed tomography of the thorax of a patient
with severe emphysema. Large bullae in both lungs and severe
panlobular emphysema, rarefaction of pulmonary parenchyma
and pulmonary vessels.
Role of a1-antitrypsin in health and disease 1133genes can be found in the circulation). Therefore, individuals
heterozygous for the Z allele (MZ) have 50e60% while indi-
viduals homozygous for the Z allele (ZZ) have only 10e15% of
the normal MM AAT value (0.8 mg/ml or  11 mmol/L).73
Guidelines for thediagnostic strategies andmanagement of
AATD were published by the ERS/ATS in 2003.74 In general,
measurement of the serum AAT concentration is the first step
in the algorithm for diagnosis of AATD. However, AAT is an
acute-phase protein and its synthesis may be up-regulated
during inflammation. Therefore, it is recommended that
C-reactiveprotein (CRP) levels aredetermined simultaneously
and that AAT concentration results are rejected if CRP levels
are abnormal. On the other hand, if the serum concentration
of AAT is below normal, characterization of AAT geno- and
phenotype is recommended. All newborns with prolonged
jaundice or nonspecific signs of liver disease should be
screened for AATD. Adults with chronic respiratory diseases,
such as COPD, not fully reversible bronchial asthma, bronchi-
ectasis, immotile cilia syndrome, frequentairway infectionsor
indeterminate liver disease, should be tested once in their
lives. In addition to the index case, relatives need to be
screened in order to identify symptom-free carriers, and, if
necessary, to recommend prophylactic measures.
Clinical manifestations of AATD
Lung disease in AATD
It is generally accepted that ZZ AATD comprises about 1e2%
of all COPD cases, and that heterozygous MZ and MS have no
risk for development of COPD. However, a recent German
study using a targeted screening program including 2696
subjects identified 268 (ZZ), 488 (MZ), 97 (MS) and 53 (SZ)
with AATD, and 16 with rare genotypes.75 The data from the
study carried out in Denmark showed that the frequency of
AATD among COPD patients is 0.8% for ZZ and 2.4% for MZ
genotype.65 In the Lithuanian cohort, consisting of 1167
patients with moderate to severe COPD, it was found that 40
(3.4%) are MZ, 39 (3.3%) MS, 1 (0.1%) SS, 3 (0.3%) SZ and 8
(0.7%) ZZ.76 Current literature indicates that asthma signs
and symptoms are common in AATD with or without COPD
and that bronchodilator response is a risk factor for FEV1
decline.13 The British Registry of patients with AATD repor-
ted the presence of asthma in about 11% of cases, and an
increased prevalence of the MS (18%) and MZ (7%) genotypes.
AATD was found in Puerto Rican children attending an
asthma clinic.77 These findings suggest that not only severe
ZZ, but also mild, heterozygous (MS, MZ, SZ) AATD may be
a risk factor for developing airways pathology.
Severe pulmonary impairment, manifesting as COPD and
panacinar lung emphysema (Fig. 2), may be expected if the
AAT serum concentration is below the protective threshold
of 35% of the normal mean value (0.8 mg/ml or  11 mmol/
L). Pulmonary symptoms, such as cough, sputum expecto-
ration, and dyspnea may occur by the age of 30e40 years.
Up to 20% of symptomatic patients develop bronchial
hyperreactivity. The course of the disease is progressive and
may lead to severe respiratory insufficiency. As in COPD,
which is unrelated to AATD, typical findings are repeated
acute exacerbations with increase of symptoms and wors-
ening of the general condition. In the majority of cases, thecause of exacerbations is believed to be airway infection.
The frequency of exacerbations seems to be associated with
the progression of pulmonary emphysema and correlates
with the decline of pulmonary function. The disease may
progress faster if additional risk factors are present, such as
tobacco smoking or (occupational) air pollutants. The mean
life expectancy of ZZ AATD patients is 48e52 years for
smokers and 60e68 years for nonsmokers.78 Today it is
widely accepted that the most important problem behind
AATD-related emphysema is a reduction in anti-elastase
defense. Either an increase in elastase burden (which might
happen with cigarette smoking or pulmonary infection) or
the quantitative deficiency of an inhibitor of neutrophil
elastase (inherited AATD) can lead to an elastase/anti-
elastase imbalance that accelerates lung tissue breakdown.
Most recent experimental data show that cigarette smoke
accelerates polymerization of Z AAT by oxidative modifica-
tion, which in so doing further reduces pulmonary defenses
and increases neutrophil influx into the lungs (Fig. 3). These
novel findings provide a molecular explanation for the
striking observation of premature emphysema in ZZ AATD
subjects who smoke and raise the prospect of anti-oxidant
therapy in AATD- related COPD.79
Liver disease in AATD
Today it is well established that the Z, and also Siiyama
(Ser53Phe) and Mmalton (52Phe del) variants of AAT, form
polymers and are retained in the endoplasmic reticulum (ER)
of hepatocytes.61 The polymers of Z-mutant AAT can be
identified by microscopy in diastase resistant inclusion
bodies reacting positively with PAS-staining (Periodic acid-
Schiff). This accumulation of abnormally folded AAT protein
is thought to be associated with increased risk for liver
diseases. Research from several laboratories has identified
a possible role for ER stress in Z AAT-induced hepatocyte
Table 2 Disease manifestations in a-1 Antitrypsin defi-
ciency other than the lung and liver.
Disease Reference number
Panniculitis 106, 107
ANCA-positive vasculitis 72, 108
Rheumatoid arthritis 100, 109
Chronic rhinosinusitis 110, 111
Acute Uveitis 112
Pancreatitis 113e115
Inflammatory bowel disease 116, 117
Celiac disease 118, 119
Peptic ulcer disease 120, 121
Diabetes 105, 122
Islet cell hyperplasia 6, 123
Renal disease 124e126
Fibromyalgia 127, 128
Idiopathic granulomatous mastitis 129
Peripherial neuropathy 130
Aneurisms 131e134
Coronary atherosclerosis 135
Cancer 136e139
Figure 3 Schematic diagram depicting the role of Z a1-
Antitrypsin (AAT) in the development of liver and lung diseases.
The pathogenesis of AATD-related liver disease is based on the
aberrant folding and polymerization of AAT protein in the
hepatocytes. Polymeric Z AAT is also found in the plasma,
bronchoalveolar lavage fluid and in the alveolar walls of Z AATD
individuals. Cigarette smoke accelerates polymerization of Z
AAT by oxidative modification,79 and further reduces anti-
elastase defense and increases neutrophil influx into the lungs.
1134 S.M. Janciauskiene et al.injury; however, the causative role of ER stress in human
liver diseases has yet to be proven.80,81 Interestingly, current
studies provide new evidence that ERManI, a putative ER
mannosidase, plays a critical role in distinguishing and tar-
geting misfolded glycoproteins for ER-associated degrada-
tion.82 Therefore, genetically low levels of ERManI in
subjects with AATD may impair the liver’s capacity to deal
with the accumulation of misfolded Z AAT and accelerate
the development of end-stage liver disease.83,84
In infants liver disease associated with ZZ AATD typically
presents as neonatal cholestatic jaundice, which often
subsides spontaneously after a few months. However, the
outcome in childhood and adolescence varies a lot, ranging
from normalization of liver test results to early cirrhosis
requiring liver transplantation.64,85 Even in children with an
apparently favorable outcome, a significant degree of liver
fibrosis may be present.86 It is well known that ZZ AATD
individuals, who do not develop liver disease in childhood,
have increased risk of liver cirrhosis and hepatocellular
carcinoma later in adulthood. Notably, AATD may be a rele-
vant cause for liver cirrhosis, after viral hepatitis, alcohol
abuse, and chronic cholangitis. From retrospective studies it
is known that up to 25% of those with ZZ AATD may suffer
from liver cirrhosis or liver cancer in late adulthood.87
However, in adults the association between the ZZ geno-
type and liver disease is still unclear, and the incidence of
such an association varies considerably.88 Cirrhosis in ZZ
AATD individuals may become clinically apparent at any age,
with the peak incidence typically occurring in elderly never-
smokers who have survived without developing severe
emphysema. Aside from low plasma AAT levels, laboratory
and other clinical features of affected individuals are
indistinguishable from those with cirrhosis of any etiology.89
Therefore, in the absence of specific biomarkers and lack of
firm evidence regarding optimal follow-up and preventivestrategies, the regular assessment of simple liver function
tests is typically recommended in elderly individuals with
AATD who lack liver symptoms.
Disease manifestations other than the lung and
liver
Diseases other than lung and liver diseases have been
associated with AATD, but their association with AATD is
less clear. Indeed, the multiple protective role(s) of AAT
described above suggest that the deficiency of that protein
may worsen the pathogenesis of other diseases rather than
causing them. To date fewer than 50 cases of panniculitis
associated with various phenotypes of AATD have been
reported.90 Panniculitis characteristically presents as red,
painful nodular lesions91,92 and clinical features that
distinguish the AATD-associated panniculitis include higher
frequency of ulceration, a vigorous neutrophilic response
and histological evidence of both necrosis and elastin
breakdown.93 In support of AATD as a contributor to the
inflammatory pathogenesis of panniculitis, a few case
reports provide evidence that the infusion of purified
pooled human AAT induces a rapid clinical resolution of
panniculitis.94e96
The putative association between AATD and vasculitis
(Wegener’s granulomatosis) is based on the fact that AATD
variants occur more frequently among individuals with
multisystem vascultitis anti-neutrophilic cytoplasmic anti-
bodies (C-ANCA) or anti-protease-3 (PR-3) and glomerulo-
nephritis.97,98 Moreover, since AAT plays an important role in
inhibiting PR3, it has been suggested that AATD could trigger
an autoimmune response due to increased extracellular
exposure to PR3.99 Alternatively, although unproven, it is
conceivable that circulating Z AAT polymers could prompt
a vascular response.
Several reports have described AATD patients having both
liver disease and rheumatoid arthritis100 and larger studies
Role of a1-antitrypsin in health and disease 1135fromCanadaand Swedenhave shownan increased frequency
of AATD phenotypes in patients with rheumatoid arthritis
compared to population frequencies.101,102 In addition, in
the setting of AATD-associated chronic liver disease, renal
disease is often seen in children and young adults.103,104
Numerous reports have also associated AATD and pancrea-
titis, inflammatory bowel disease, celiac disease, peptic
ulcer disease, fibromuscular dysplasia, aneurysms and
coronary atherosclerosis. AATD association with psoriasis,
chronic urticaria, multiple sclerosis, fibromyalgia, ocular
allergy, acute uveitis and other conditions have been
reported (Table 2). However, further investigations are
needed before these putative associations between AATD
and various diseases are confirmed. In general, one can
predict that in AATD, the protective effects of AAT protein
are much lower and therefore a more aggressive inflamma-
tory course of disease can be seen in AATD carriers.
Finally, recent studies have raised the possibility of an
association between AAT and diabetes. In support of this,
a few clinical studies demonstrated that plasma AAT levels
and activity are lower in diabetic patients than in non-
diabetic controls.105 It has also been demonstrated that
over-expression of AAT significantly reduces insulitis and
prevents the development of overt hyperglycemia in non-
obese diabetic (NOD) mice.46 In addition, it has been
shown that administration of clinical-grade human AAT
prolongs pancreatic islet allograft survival and exhibits
cytoprotective effects.29 Studies examining the role of
AAT in diabetes are an area of intense and ongoing
investigation.
Conclusions
Despite tremendous progress made in the field of AATD
since its first description by Laurell and Eriksson,140 key
challenges still remain. Clearly the role of AAT in inflam-
matory processes in the lung has until recently been over-
simplified. Although we believe that the effects of AAT are
predominantly anti-inflammatory, the actual impact of AAT
on inflammatory disease may depend not only on the
relative concentration of native, inhibitory and non-inhib-
itory, modified forms of AAT, but also on the inflammatory
context in which they are expressed. The formation of post-
translational modified forms of AAT may lead to a func-
tional deficiency of AAT, even if the individual has a normal
level of AAT, and the modified forms of AAT may themselves
express biological activities. Studies characterizing the
inhibitor-independent activity of AAT and its modified forms
are incomplete, particularly with regard to an under-
standing of the signaling mechanisms involved. Delineation
of these will not only help us to further understand the role
of AAT in the pathogenesis of inflammatory disease, but
may also facilitate the identification of new and effective
anti-inflammatory therapies.Conflict of interest
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